C71T
CANCELLED SECTION 71
06/03/2026
Voltar para busca
Dado oficial do USPTO
FLEXISEQ
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
31/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 10
Data de depósito
12/12/2011
Data de registro
26/11/2013
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/03/2026
Última transação
31/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Berkshire, GB
Examinador
BUONGIORNO, CHRISTOPHER L
Unidade examinadora
L20
Titulares e representantes
Titulares
Pro Bono Bio Entrepreneur Limited
Pro Bono Bio Entrepreneur Limited
Representantes
Roberta S. Bren MUNCY, GEISSLER, OLDS & LOWE, P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Surfactants and lipids for use in the manufacture of personal care productschemical products for in vitro and in vivo use in research and development
Classe 5
Pharmaceutical preparations and substances for the treatment of pain and inflammation; veterinary and sanitary preparations and substances for the treatment of pain and inflammation; chemical preparations for pharmaceutical purposesfor the treatment of pain and inflammation; diagnostic preparations and substances for medical purposes for in vivo use; pharmaceuticals for treating osteoarthritisoncologycardiovascular diseaserespiratory diseaseinflammationinfectiongastrointestinal diseases and central nervous system diseases; diagnostic preparation for medical and veterinary use; topical and parenteral preparations of vesiclesliquids or gels for the treatment of pain and inflammation; chemical preparations for the treatment of pain and inflammation in the form of vesicles for medical and veterinary purposes; pharmaceutical preparations being chemical membranes and chemical aggregates for medical and veterinary purposes; pharmaceutical preparations of arachidonic acids for the treatment of pain and inflammation; dispersions and dry preparations of liposomal active substance carriers for use as a pharmaceuticalcosmetic substance carrierin the nature of a liquidgelcreamlotion or lipid; cosmeceutical preparations in the nature of medicated cosmetics; local anesthetics; steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines; immunotherapeutic vaccines; topical and parenteral lipids for use in the treatment of pain and inflammation; medicated creamsmedicated dispersionsmedicated lotionsmedicated ointmentsmedicated gelsmedicated solutionsmedicated spraysmedicated lacquers and pharmaceutical solutions which form a film on the skin for the treatment of pain and inflammation; surfactants for medical use in the treatment of or prevention of cancerinfectious diseasefungal diseasesdisease caused by parasiteseye diseasediseases of the central and peripheral nervous systemscardiovascular diseasediseases affecting the immune systeminflammatory diseasessingle gene disordersdiseases of the mouthteethskinhair and earbone and blood diseases and reproductive system disordersthe treatment of inflammationasthmaatopic eczemadishydrotic hand eczemaplaque type psoriasisseborrhoeic eczemaacne vulgarisbronchospasmatherothrombotic cardiovascular disordersvenous thrombotic disorderspaindysmenorrheahypercholesterolemiahypertriglyceridemiafatty acid metabolismmetal or other toxicityAlzheimer's diseasegoutmacular degenerationage-related macular degenerationfungal infection and disorders related to fatty acid deficiencies
Classe 10
Medical devices in the nature of a carrier with nanostructures which cross through the skin for the treatment of pain and inflammation associated with osteoarthritis; molecular filtering devices for medical usea liquid or gel as a drug delivery device which filters through the skin and has a physical therapeutic effect at the point of complaint; medicalveterinary and surgical devicesa medical device which acts as a drug delivery system in the nature of non-pharmaceutical nanostructures that migrate through the skin and have a physical therapeutic effect at the point of complaint ; inhalers for medical purposes sold empty; injection devicesmedical syringes and medical fluid injectors; medical instruments and devices for the administration of pain relief therapy and prophylaxis preparations and substances
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
26/11/2022
RNWL
INTERNATIONAL REGISTRATION RENEWED
30/12/2021
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
07/11/2020
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
01/10/2020
INPC
INVALIDATION PROCESSED
01/10/2020
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
08/09/2020
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
08/01/2020
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
08/01/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/01/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/12/2019
ES75
TEAS SECTION 71 & 15 RECEIVED
04/11/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/08/2019
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
26/11/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/03/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/03/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/03/2014
FICS
FINAL DISPOSITION NOTICE SENT TO IB
27/02/2014
FIMP
FINAL DISPOSITION PROCESSED
27/02/2014
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
26/02/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
26/11/2013
GPNX
NOTIFICATION PROCESSED BY IB
15/09/2013
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/09/2013
PUBO
PUBLISHED FOR OPPOSITION
10/09/2013
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
28/08/2013
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
28/08/2013
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/08/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/08/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/08/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/07/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/07/2013
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
15/07/2013
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/03/2013
GNFR
FINAL REFUSAL E-MAILED
11/03/2013
CNFR
FINAL REFUSAL WRITTEN
11/03/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/02/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/02/2013
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/02/2013
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/02/2013
ALIE
ASSIGNED TO LIE
08/02/2013
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/02/2013
RFNT
REFUSAL PROCESSED BY IB
01/09/2012
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
15/08/2012
RFRR
REFUSAL PROCESSED BY MPU
15/08/2012
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/08/2012
MAFR
APPLICATION FILING RECEIPT MAILED
14/08/2012
CNRT
NON-FINAL ACTION WRITTEN
13/08/2012
DOCK
ASSIGNED TO EXAMINER
08/08/2012
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/08/2012
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/08/2012
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace FLEXISEQ ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.